Literature DB >> 7544674

Bowel obstruction in home-care cancer patients: 4 years experience.

S Mercadante1.   

Abstract

Conservative management of bowel obstruction in advanced cancer patients has been recognized as efficacious in controlling distressing symptoms such as nausea, vomiting and pain. A retrospective analysis of prevalence, treatment and outcome was performed. A group of 25 patients with signs of bowel obstruction were studied from 1001 consecutive patients receiving palliative care at home. A score for total distress was calculated to assess the gastrointestinal symptoms at diagnosis, after 1 week of treatment and 1 day before death. The mean survival was 19 days. Six patients were admitted to hospital, 3 of whom underwent surgery and died in the immediate postoperative period. The patients diagnosed in hospital and discharged received a nasogastric tube (7 cases) and a central venous line. The nasogastric tube was removed after gastrointestinal secretions had been controlled by a combination of drugs, and parenteral nutrition or hydration, mainly started in hospital, was discontinued only a few days before death (13 cases, mean duration 19 days). The distress symptom score was statistically reduced after 1 week of treatment and on the day before death when compared to the referral time. The most frequent combination of drugs was octreotide, haloperidol and low doses of morphine. A subcutaneous route was preferred for administering the drugs. Utilization of a wide range of drugs permits good symptom control for bowel obstruction in patients followed at home.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544674     DOI: 10.1007/bf00368889

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  14 in total

1.  Home palliative care: results in 1991 versus 1988.

Authors:  S Mercadante; G Genovese; J A Kargar; S Maddaloni; S Roccella; L Salvaggio; M T Simonetti
Journal:  J Pain Symptom Manage       Date:  1992-10       Impact factor: 3.612

2.  Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction.

Authors:  F De Conno; A Caraceni; E Zecca; E Spoldi; V Ventafridda
Journal:  J Pain Symptom Manage       Date:  1991-11       Impact factor: 3.612

3.  Symptom control in terminally ill patients with malignant bowel obstruction (MBO).

Authors:  R L Fainsinger; K Spachynski; J Hanson; E Bruera
Journal:  J Pain Symptom Manage       Date:  1994-01       Impact factor: 3.612

Review 4.  Nutrition in cancer patients: an update and review of our experience. Issues in symptom control. Part 3.

Authors:  E Bruera; R N MacDonald
Journal:  J Pain Symptom Manage       Date:  1988       Impact factor: 3.612

5.  Parenteral nutrition at home in advanced cancer patients.

Authors:  S Mercadante
Journal:  J Pain Symptom Manage       Date:  1995-08       Impact factor: 3.612

6.  Non-operative management of malignant intestinal obstruction.

Authors:  W H Isbister; P Elder; L Symons
Journal:  J R Coll Surg Edinb       Date:  1990-12

7.  Management of bowel obstruction in advanced and terminal cancer patients.

Authors:  C Ripamonti; F De Conno; V Ventafridda; B Rossi; M J Baines
Journal:  Ann Oncol       Date:  1993-01       Impact factor: 32.976

8.  Intestinal obstruction in patients with widespread intraabdominal malignancy.

Authors:  A Chan; R K Woodruff
Journal:  J Pain Symptom Manage       Date:  1992-08       Impact factor: 3.612

9.  Palliation of malignant intestinal obstruction using octreotide.

Authors:  D Khoo; E Hall; R Motson; J Riley; K Denman; J Waxman
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

10.  The management of inoperable gastrointestinal obstruction in terminal cancer patients.

Authors:  V Ventafridda; C Ripamonti; A Caraceni; E Spoldi; L Messina; F De Conno
Journal:  Tumori       Date:  1990-08-31
View more
  9 in total

1.  Can malignant bowel obstruction in advanced cancer patients be treated at home?

Authors:  Giampiero Porzio; Federica Aielli; Lucilla Verna; Brigida Galletti; Ghazaleh Shoja E Razavi; Corrado Ficorella
Journal:  Support Care Cancer       Date:  2010-09-25       Impact factor: 3.603

Review 2.  Home parenteral nutrition for people with inoperable malignant bowel obstruction.

Authors:  Anne Marie Sowerbutts; Simon Lal; Jana Sremanakova; Andrew Clamp; Chris Todd; Gordon C Jayson; Antje Teubner; Anne-Marie Raftery; Eileen J Sutton; Lisa Hardy; Sorrel Burden
Journal:  Cochrane Database Syst Rev       Date:  2018-08-10

Review 3.  Nutrition in cancer patients.

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1996-01       Impact factor: 3.603

4.  Acute impact of home parenteral nutrition in patients with late-stage cancer on family caregivers: preliminary data.

Authors:  Lidia Santarpia; Federico Bozzetti
Journal:  Support Care Cancer       Date:  2017-09-18       Impact factor: 3.603

Review 5.  The role of parenteral nutrition in patients with malignant bowel obstruction.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2019-07-17       Impact factor: 3.603

6.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 7.  Recent advances in malignant bowel obstruction: an interface of old and new.

Authors:  Vinaya Potluri; Donna S Zhukovsky
Journal:  Curr Pain Headache Rep       Date:  2003-08

Review 8.  Enteral and parenteral nutrition in the perioperative period: state of the art.

Authors:  Salim Abunnaja; Andrea Cuviello; Juan A Sanchez
Journal:  Nutrients       Date:  2013-02-21       Impact factor: 5.717

9.  Ensuring competency in end-of-life care: controlling symptoms.

Authors:  Frank D Ferris; Charles F Von Gunten; Linda L Emanuel
Journal:  BMC Palliat Care       Date:  2002-07-30       Impact factor: 3.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.